Standard

Novel Multistage Subunit Mycobacterium tuberculosis Nanoparticle Vaccine Confers Protection Against Experimental Infection in Prophylactic and Therapeutic Regimens. / Tukhvatulin, Amir I.; Dzharullaeva, Alina S.; Vasina, Daria V. et al.

In: Vaccines, Vol. 14, No. 1, 5, 2026.

Research output: Contribution to journal › Article › peer-review

Harvard

Tukhvatulin, AI, Dzharullaeva, AS, Vasina, DV, Fursov, MV, Izhaeva, FM, Kleymenov, DA, Shcherbinin, DN, Polyakov, NB, Solovyev, AI, Zhukhovitsky, VG, Zhitkevich, AS, Gordeychuk, IV, Litvinova, AM, Manuylov, VA, Potapov, VD, Tkachuk, AP, Gushchin, VA, Logunov, DY & Gintsburg, AL 2026, 'Novel Multistage Subunit Mycobacterium tuberculosis Nanoparticle Vaccine Confers Protection Against Experimental Infection in Prophylactic and Therapeutic Regimens', Vaccines, vol. 14, no. 1, 5. https://doi.org/10.3390/vaccines14010005

APA

Tukhvatulin, A. I., Dzharullaeva, A. S., Vasina, D. V., Fursov, M. V., Izhaeva, F. M., Kleymenov, D. A., Shcherbinin, D. N., Polyakov, N. B., Solovyev, A. I., Zhukhovitsky, V. G., Zhitkevich, A. S., Gordeychuk, I. V., Litvinova, A. M., Manuylov, V. A., Potapov, V. D., Tkachuk, A. P., Gushchin, V. A., Logunov, D. Y., & Gintsburg, A. L. (2026). Novel Multistage Subunit Mycobacterium tuberculosis Nanoparticle Vaccine Confers Protection Against Experimental Infection in Prophylactic and Therapeutic Regimens. Vaccines, 14(1), [5]. https://doi.org/10.3390/vaccines14010005

Vancouver

Tukhvatulin AI, Dzharullaeva AS, Vasina DV, Fursov MV, Izhaeva FM, Kleymenov DA et al. Novel Multistage Subunit Mycobacterium tuberculosis Nanoparticle Vaccine Confers Protection Against Experimental Infection in Prophylactic and Therapeutic Regimens. Vaccines. 2026;14(1):5. doi: 10.3390/vaccines14010005

Author

Tukhvatulin, Amir I. ; Dzharullaeva, Alina S. ; Vasina, Daria V. et al. / Novel Multistage Subunit Mycobacterium tuberculosis Nanoparticle Vaccine Confers Protection Against Experimental Infection in Prophylactic and Therapeutic Regimens. In: Vaccines. 2026 ; Vol. 14, No. 1.

BibTeX

@article{85a8eb8fc25a4e65870a2b241e1e2ca2,
title = "Novel Multistage Subunit Mycobacterium tuberculosis Nanoparticle Vaccine Confers Protection Against Experimental Infection in Prophylactic and Therapeutic Regimens",
abstract = "Background/Objectives: Tuberculosis (TB) remains the leading cause of death from a single infectious agent worldwide. In line with the World Health Organization{\textquoteright}s (WHO) goal to end TB by 2035, the rapid development and clinical implementation of new, effective vaccines is urgently needed. To support global TB control efforts, we developed a novel candidate subunit multistage vaccine. Methods: This vaccine incorporates multiple Mycobacterium tuberculosis antigens expressed during both dormant and active stages of infection, fused into a single recombinant protein (ESAT6-CFP10-Ag85A-Rv2660c-Rv1813c). The antigen was encapsulated in biodegradable poly(D,L-lactide-co-glycolide) (PLGA) nanoparticles along with the pattern recognition receptor (PRR) agonists monophosphoryl lipid A (MPLA) and muramyl dipeptide (MDP), which function as adjuvants. Results: Using a mixed intramuscular/nasal prime-boost regimen, the vaccine elicited a mixed Th1/Th17 cell-mediated immune response, as well as a robust humoral response characterized by sustained systemic IgG (lasting at least one year) and prominent local secretory IgA. The vaccine demonstrated protective efficacy as a prophylactic booster following BCG priming in both murine and guinea pig models and was also effective in a therapeutic setting in a murine infection model. Conclusions: The results of this study provide empirical evidence that multistage tuberculosis vaccines represent a promising strategy for achieving global TB control.",
keywords = "Mycobacterium tuberculosis, TB, multi-stage vaccines, subunit vaccines, pattern-recognition receptors, PRR agonists",
author = "Tukhvatulin, {Amir I.} and Dzharullaeva, {Alina S.} and Vasina, {Daria V.} and Fursov, {Mikhail V.} and Izhaeva, {Fatima M.} and Kleymenov, {Denis A.} and Shcherbinin, {Dmitry N.} and Polyakov, {Nikita B.} and Solovyev, {Andrey I.} and Zhukhovitsky, {Vladimir G.} and Zhitkevich, {Alla S.} and Gordeychuk, {Ilya V.} and Litvinova, {Anna M.} and Manuylov, {Victor A.} and Potapov, {Vasiliy D.} and Tkachuk, {Artem P.} and Gushchin, {Vladimir A.} and Logunov, {Denis Y.} and Gintsburg, {Alexander L.}",
note = "This study was conducted with the support of the Ministry of Education and Science of Russia within the framework of the Federal Targeted Program Pharma-2020 (State Contract No. 14.N08.11.0192 dated 22 November 2017) and the State Assignment of the Ministry of Health of Russia No. 125020501441-9. TEM was conducted at the Chumakov FSC R&D IBP RAS (Institute of Poliomyelitis) as part of fundamental research assignment No. 426.",
year = "2026",
doi = "10.3390/vaccines14010005",
language = "English",
volume = "14",
journal = "Vaccines",
issn = "2076-393X",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "1",

}

RIS

TY - JOUR

T1 - Novel Multistage Subunit Mycobacterium tuberculosis Nanoparticle Vaccine Confers Protection Against Experimental Infection in Prophylactic and Therapeutic Regimens

AU - Tukhvatulin, Amir I.

AU - Dzharullaeva, Alina S.

AU - Vasina, Daria V.

AU - Fursov, Mikhail V.

AU - Izhaeva, Fatima M.

AU - Kleymenov, Denis A.

AU - Shcherbinin, Dmitry N.

AU - Polyakov, Nikita B.

AU - Solovyev, Andrey I.

AU - Zhukhovitsky, Vladimir G.

AU - Zhitkevich, Alla S.

AU - Gordeychuk, Ilya V.

AU - Litvinova, Anna M.

AU - Manuylov, Victor A.

AU - Potapov, Vasiliy D.

AU - Tkachuk, Artem P.

AU - Gushchin, Vladimir A.

AU - Logunov, Denis Y.

AU - Gintsburg, Alexander L.

N1 - This study was conducted with the support of the Ministry of Education and Science of Russia within the framework of the Federal Targeted Program Pharma-2020 (State Contract No. 14.N08.11.0192 dated 22 November 2017) and the State Assignment of the Ministry of Health of Russia No. 125020501441-9. TEM was conducted at the Chumakov FSC R&D IBP RAS (Institute of Poliomyelitis) as part of fundamental research assignment No. 426.

PY - 2026

Y1 - 2026

N2 - Background/Objectives: Tuberculosis (TB) remains the leading cause of death from a single infectious agent worldwide. In line with the World Health Organization’s (WHO) goal to end TB by 2035, the rapid development and clinical implementation of new, effective vaccines is urgently needed. To support global TB control efforts, we developed a novel candidate subunit multistage vaccine. Methods: This vaccine incorporates multiple Mycobacterium tuberculosis antigens expressed during both dormant and active stages of infection, fused into a single recombinant protein (ESAT6-CFP10-Ag85A-Rv2660c-Rv1813c). The antigen was encapsulated in biodegradable poly(D,L-lactide-co-glycolide) (PLGA) nanoparticles along with the pattern recognition receptor (PRR) agonists monophosphoryl lipid A (MPLA) and muramyl dipeptide (MDP), which function as adjuvants. Results: Using a mixed intramuscular/nasal prime-boost regimen, the vaccine elicited a mixed Th1/Th17 cell-mediated immune response, as well as a robust humoral response characterized by sustained systemic IgG (lasting at least one year) and prominent local secretory IgA. The vaccine demonstrated protective efficacy as a prophylactic booster following BCG priming in both murine and guinea pig models and was also effective in a therapeutic setting in a murine infection model. Conclusions: The results of this study provide empirical evidence that multistage tuberculosis vaccines represent a promising strategy for achieving global TB control.

AB - Background/Objectives: Tuberculosis (TB) remains the leading cause of death from a single infectious agent worldwide. In line with the World Health Organization’s (WHO) goal to end TB by 2035, the rapid development and clinical implementation of new, effective vaccines is urgently needed. To support global TB control efforts, we developed a novel candidate subunit multistage vaccine. Methods: This vaccine incorporates multiple Mycobacterium tuberculosis antigens expressed during both dormant and active stages of infection, fused into a single recombinant protein (ESAT6-CFP10-Ag85A-Rv2660c-Rv1813c). The antigen was encapsulated in biodegradable poly(D,L-lactide-co-glycolide) (PLGA) nanoparticles along with the pattern recognition receptor (PRR) agonists monophosphoryl lipid A (MPLA) and muramyl dipeptide (MDP), which function as adjuvants. Results: Using a mixed intramuscular/nasal prime-boost regimen, the vaccine elicited a mixed Th1/Th17 cell-mediated immune response, as well as a robust humoral response characterized by sustained systemic IgG (lasting at least one year) and prominent local secretory IgA. The vaccine demonstrated protective efficacy as a prophylactic booster following BCG priming in both murine and guinea pig models and was also effective in a therapeutic setting in a murine infection model. Conclusions: The results of this study provide empirical evidence that multistage tuberculosis vaccines represent a promising strategy for achieving global TB control.

KW - Mycobacterium tuberculosis

KW - TB

KW - multi-stage vaccines

KW - subunit vaccines

KW - pattern-recognition receptors

KW - PRR agonists

UR - https://www.scopus.com/pages/publications/105029118605

UR - https://www.mendeley.com/catalogue/f469a02f-c2c8-3923-b1e1-29c32fa5d148/

U2 - 10.3390/vaccines14010005

DO - 10.3390/vaccines14010005

M3 - Article

C2 - 41600921

VL - 14

JO - Vaccines

JF - Vaccines

SN - 2076-393X

IS - 1

M1 - 5

ER -

ID: 76409536